Therapeutic agents comprising pro-apoptotic proteins

Details Therapeutic agents comprising pro-apoptotic proteins Therapeutic agents comprising pro-apoptotic proteins

2008-05-13

2008-05-13

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

11415342

ABSTRACT:
The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.

REFERENCES:
patent: 4263279 (1981-04-01), Sela et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4771128 (1988-09-01), Ferris et al.
patent: 4801578 (1989-01-01), Monsigny et al.
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4894225 (1990-01-01), Zimmerman
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4962188 (1990-10-01), Frankel
patent: 4963354 (1990-10-01), Shepard et al.
patent: 4971792 (1990-11-01), Steplewski et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 5017371 (1991-05-01), Cummins
patent: 5019368 (1991-05-01), Epstein et al.
patent: 5032521 (1991-07-01), White et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5135736 (1992-08-01), Anderson et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5621083 (1997-04-01), Better et al.
patent: 5624827 (1997-04-01), Rosenblum et al.
patent: 5631348 (1997-05-01), Rosenblum et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 5851829 (1998-12-01), Marasco et al.
patent: 6084073 (2000-07-01), Piatak, Jr.
patent: 6099842 (2000-08-01), Pastan et al.
patent: 6140066 (2000-10-01), Lorberboum-Galski et al.
patent: 6197528 (2001-03-01), Wu et al.
patent: 6214974 (2001-04-01), Rosenblum et al.
patent: 6218165 (2001-04-01), Estell et al.
patent: 6306626 (2001-10-01), Rosenblum et al.
patent: 6309873 (2001-10-01), Torrens et al.
patent: RE37462 (2001-12-01), Rosenblum et al.
patent: 6531133 (2003-03-01), Lorberboum-Galski et al.
patent: 6599505 (2003-07-01), Rosenblum
patent: 6639054 (2003-10-01), Alibhai et al.
patent: 6669938 (2003-12-01), Rosenblum et al.
patent: 6750329 (2004-06-01), Rosenblum et al.
patent: 2002/0090374 (2002-07-01), Yarkoni et al.
patent: 2003/0073163 (2003-04-01), Fernandez et al.
patent: 2003/0134302 (2003-07-01), Fernandez et al.
patent: 2003/0176331 (2003-09-01), Rosenblum et al.
patent: 2003/0186384 (2003-10-01), Barth et al.
patent: 2004/0009477 (2004-01-01), Fernandez et al.
patent: 2004/0013691 (2004-01-01), Rosenblum et al.
patent: 2005/0100528 (2005-05-01), Rosenblum
patent: 2005/0214307 (2005-09-01), Rosenblum
patent: B79527/87 (1988-04-01), None
patent: B82047/87 (1988-06-01), None
patent: A13017/88 (1988-09-01), None
patent: A21725/88 (1989-03-01), None
patent: A30753/89 (1989-08-01), None
patent: 1339798 (1998-04-01), None
patent: 0118365 (1984-03-01), None
patent: 0160446 (1985-04-01), None
patent: 0150126 (1985-07-01), None
patent: 0184369 (1985-11-01), None
patent: 0226418 (1986-12-01), None
patent: 0222360 (1987-05-01), None
patent: 0256714 (1988-02-01), None
patent: 0281070 (1988-09-01), None
patent: 0305967 (1989-03-01), None
patent: 0336631 (1989-10-01), None
patent: 0350230 (1990-01-01), None
patent: 0396387 (1990-11-01), None
patent: 0893493 (1999-01-01), None
patent: 1564666 (1978-01-01), None
patent: 2148299 (1985-05-01), None
patent: 86121 (1981-07-01), None
patent: 62209098 (1986-12-01), None
patent: 190200 (1987-08-01), None
patent: WO 85/00974 (1984-08-01), None
patent: WO 86/05098 (1985-07-01), None
patent: WO 86/02945 (1986-05-01), None
patent: WO 87/00056 (1986-06-01), None
patent: WO 88/09343 (1988-12-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/00999 (1989-02-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 90/00405 (1990-01-01), None
patent: WO 91/16071 (1991-10-01), None
patent: WO 94/26910 (1994-11-01), None
patent: WO 97/22364 (1997-06-01), None
patent: WO 97/46259 (1997-12-01), None
patent: WO 98/37901 (1998-09-01), None
patent: WO 99/29721 (1999-06-01), None
patent: WO 99/40198 (1999-08-01), None
patent: WO 99/43840 (1999-09-01), None
patent: WO 99/45128 (1999-09-01), None
patent: WO 99/49059 (1999-09-01), None
patent: WO 99/51620 (1999-10-01), None
patent: WO 99/51766 (1999-10-01), None
patent: WO 00/26406 (2000-05-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 00/42179 (2000-07-01), None
patent: WO 02/42420 (2002-05-01), None
patent: WO 02/074979 (2002-09-01), None
patent: WO 03/002598 (2003-01-01), None
Aboud-Pirak et al., “Cytotoxic activity of daunorubicin or vindesine conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells,”Biochem. Pharmacol.,38:641-648, 1989.
Adams et al., “The Bcl-2 Protein Family: Arbiters of Cell Survival,”Science, 281:1322-1326, 1998.
Aggarwal and Kohr, “Human tumor necrosis factor,”Methods in Enzymology, 116:448-456, 1986.
Alfthan et al., “Properties of single-chain antibody containing different linker peptides,”Protein Engineering; 8:725-731, 1995.
Alkan et al., “Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies,”J. Interferon Res., 4(3):355-363, 1984.
Alley et al., “Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay,”Cancer Res., 48:589-601, 1988.
Aqeilan et al., “Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy,”FEBS Letts., 457:271-276, 1999.
Ardekani et al., “Molecular profiling of cancer and drug-induced toxicity using new proteomic technologies,”Current Therapeutic Res., 62:803-819, 2001.
Arnon et al., “Monoclonal antibodies for immunotargeting of drugs in cancer therapy,” Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. pp. 243-256, 1985.
Arora, “Vascular endothelial growth facto chimeric toxin is highly active against endothelial cells,”Cancer Research, 59:183-188, 1999.
Atkinson et al., “Conjugation of folate via gelonin carbohydrate residues retains ribosomal-activating properties of the toxin and permits targeting to folate receptor positive cells,”Biochem Molec. Biol., 276(30):27930-27935, 2001.
Barbieri and Stirpe, “Ribosome-inactivating proteins from plants: Properties and possible uses,”Cancer Surveys, 1(3):489-520.
Batra at al., “Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin,”Proc. Natl. Acad. Sci., 86:8545-8549, 1989.
Batra at al., “Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv),”Mol. Cell. Biol.11:2200-2205, 1991.
Bendig, “Humanization of rodent monoclonal antibodies by CDR grafting,”Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
Berkower, “The promise and pitfalls of monoclonal antibody therapeutics,”Current Opinion in Biotechnology, 7:622-628, 1996.
Better et al., “Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties,”J. Biol. Chem., 269:9644-9650, 1994.
Bird et al., “Single-chain antigen-binding proteins,”Science, 242:423-426, 1988.
Bjorn et al., “Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins,”Cancer Res., 45:1214-1221, 1985.
Blair et al., “Linkage of cytotoxic agents to immunoglobu

Affiliated with

Also associated with

Rating

Therapeutic agents comprising pro-apoptotic proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents comprising pro-apoptotic proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents comprising pro-apoptotic proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3928300